Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Liabilities: 2022-2025

Historic Total Liabilities for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $595.5 million.

  • Axsome Therapeutics' Total Liabilities rose 27.10% to $595.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 27.10%. This contributed to the annual value of $511.5 million for FY2024, which is 28.75% up from last year.
  • Axsome Therapeutics' Total Liabilities amounted to $595.5 million in Q3 2025, which was up 5.08% from $566.7 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Total Liabilities registered a high of $595.5 million during Q3 2025, and its lowest value of $73.9 million during Q1 2022.
  • Over the past 3 years, Axsome Therapeutics' median Total Liabilities value was $445.4 million (recorded in 2024), while the average stood at $442.9 million.
  • Data for Axsome Therapeutics' Total Liabilities shows a peak YoY surged of 275.52% (in 2023) over the last 5 years.
  • Axsome Therapeutics' Total Liabilities (Quarterly) stood at $221.9 million in 2022, then surged by 79.01% to $397.3 million in 2023, then increased by 28.75% to $511.5 million in 2024, then climbed by 27.10% to $595.5 million in 2025.
  • Its Total Liabilities stands at $595.5 million for Q3 2025, versus $566.7 million for Q2 2025 and $543.5 million for Q1 2025.